Dermatology CPT® Codes for 2026 + Modifiers
Mar 18, 2026
Technically Reviewed By:
Last Updated: November 4, 2026
Kristen is a Senior Account Manager with 25 years of experience in the healthcare industry. She specializes in commercial insurance resolution, helping practices navigate payer disputes, denials, audits, and other revenue challenges.
Dermatology billing in 2026 reflects both reimbursement stabilization and structural payment reform. While the Physician Fee Schedule increase benefits E/M-heavy practices, significant technical changes affect acne procedures, skin substitute reimbursement, radiation therapy reporting, and modifier enforcement. If your team is still using last year’s templates, small documentation gaps could translate into preventable denials.
This guide outlines the most important dermatology CPT® codes and modifiers for 2026, structural payment changes, and the compliance rules practices must adopt to protect reimbursement.
Dermatology denials in 2026 aren’t random. They’re driven by structural rule changes.
We’re seeing repeat denials tied to time-based E/M documentation, improper skin substitute billing, missing -JZ/-JW modifiers, and outdated radiation coding. These aren’t isolated mistakes. They’re workflow breakdowns.
Guarantee: We’ll identify the top denial drivers in your dermatology claims and give you a clear plan to fix them.
Get My Dermatology Denial Snapshot
Contact us to receive a Denial Snapshot that shows where your dermatology revenue is breaking down and how to correct it.
The 2026 Physician Fee Schedule Stabilization
- +3.77% conversion factor increase for qualifying participants in Advanced APMs
- +3.26% increase for all other physicians
This marks the first meaningful rate increase in several years. Dermatologists who rely heavily on 99214 and 99215 visits for psoriasis, acne, eczema, and biologic management will see measurable stabilization in revenue, if documentation supports level selection.
Procedures did not get the full benefit. CMS also applied a 2.5% efficiency cut to the work value of most non-time-based services, which includes biopsies, destructions, excisions, and Mohs surgery. E/M visits are exempt. Part of the 2026 increase is a one-year boost set by law, so watch the CY 2027 final rule for what happens next.
However, increased scrutiny on time-based billing means even minor documentation gaps can result in downcoding.
Higher rates don’t help if your E/M levels are being downcoded.
We commonly see 99215 reduced to 99214 because total time isn’t clearly documented. That difference compounds quickly across high-volume dermatology practices.
Guarantee: We’ll identify where your E/M documentation is costing you revenue.
Evaluation & Management (E/M) CPT® Codes
| CPT® Code | Description |
|---|---|
| 99202–99205 | New patient office visits |
| 99212–99215 | Established patient office visits |
| 99242–99245 | Office or other outpatient consultations (payer dependent; not paid by Medicare) |
| G2211 | Medicare add-on for ongoing, longitudinal care of a serious or complex condition (eg, psoriasis on biologics); generally not payable when the visit carries modifier -25 |
2026 Time Enforcement Reminder
To bill 99215 by time, documentation must reflect at least 40 minutes of total physician or qualified health professional time on the date of service. A visit documented at 30 to 39 minutes is billed as 99214.
Total time includes the practitioner’s face-to-face and non-face-to-face work on that date, such as reviewing records and documenting, but not time spent on separately billed procedures.
Time-based billing errors are easy to fix, once you see them.
We review documentation patterns and identify where total time language, medical decision-making, or risk statements are insufficient.
Guarantee: We’ll pinpoint your E/M denial drivers and show you how to prevent repeat reductions.
CPT® Terminology Update: Acne Extraction (10040)
The descriptor for CPT® 10040 was revised for 2026. The words “acne surgery” were replaced with “extraction.” The code still describes marsupialization, opening, or removal of multiple milia, comedones, cysts, or pustules.
Why This Matters
Payment and documentation requirements for 10040 did not change, but superbills and note templates should now say “acne extraction” so the procedure name matches the current code set. 10040 carries a 10-day global period, so an E/M on the same day needs a separately documented reason and modifier -25.
Outdated terminology can trigger avoidable audits.
Even descriptor wording changes like 10040 can cause confusion if templates aren’t updated.
Guarantee: We’ll identify documentation language that’s increasing audit risk.
Skin Biopsies
| CPT® Code | Description |
|---|---|
| 11102 | Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion |
| +11103 | Tangential biopsy, each additional lesion |
| 11104 | Punch biopsy of skin, including simple closure; single lesion |
| +11105 | Punch biopsy, each additional lesion |
| 11106 | Incisional biopsy of skin (eg, wedge), including simple closure; single lesion |
| +11107 | Incisional biopsy, each additional lesion |
Biopsy Hierarchy Rule
Only one primary biopsy code (11102, 11104, or 11106) is reported per encounter. When different techniques are used on different lesions, report the primary code for the highest-ranked technique (incisional, then punch, then tangential), and report every other lesion with the add-on code that matches its own technique.
Example: a punch biopsy and two shave biopsies are reported as 11104 + 11103 x2.
Mixed biopsy technique errors are a common denial trigger.
We routinely see improper add-on pairing or technique hierarchy mistakes reduce payment.
Guarantee: We’ll review your biopsy reporting and correct high-risk coding patterns.
Destruction of Lesions and Mohs Surgery
| CPT® Code | Description |
|---|---|
| 17000 | Destruction of premalignant lesions (eg, actinic keratoses); first lesion |
| +17003 | Destruction of premalignant lesions; second through 14 lesions, each |
| 17004 | Destruction of premalignant lesions; 15 or more lesions (reported alone, not with 17000 or 17003) |
| 17110 | Destruction of benign lesions other than skin tags or vascular lesions (eg, warts); up to 14 lesions |
| 17111 | Destruction of benign lesions; 15 or more lesions |
| 17311 | Mohs surgery, head, neck, hands, feet, genitalia, or other areas involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks |
| +17312 | Mohs surgery, same locations; each additional stage, up to 5 tissue blocks |
| 17313 | Mohs surgery, trunk, arms, or legs; first stage, up to 5 tissue blocks |
| +17314 | Mohs surgery, trunk, arms, or legs; each additional stage, up to 5 tissue blocks |
| +17315 | Mohs surgery, each additional block after the first 5 tissue blocks, any stage |
Excisions and Repairs
Excision codes are chosen by whether the lesion is benign or malignant, its location, and its excised diameter, which is the lesion plus the narrowest margins needed.
| CPT® Codes | Description |
|---|---|
| 11400–11446 | Excision of benign lesion, by location and excised diameter |
| 11600–11646 | Excision of malignant lesion, by location and excised diameter |
| 12001–12021 | Simple repair (included in the excision; not reported separately) |
| 12031–12057 | Intermediate repair (layered closure; reported in addition to the excision) |
| 13100–13160 | Complex repair (reported in addition to the excision) |
Most excisions carry a 10-day global period. Wait for the pathology report to choose between benign and malignant excision codes.
Phototherapy, Laser, and Photodynamic Therapy
| Code | Description |
|---|---|
| 96900 | Actinotherapy (ultraviolet light) |
| 96910 | Photochemotherapy; tar and ultraviolet B (Goeckerman) or petrolatum and ultraviolet B |
| 96912 | Photochemotherapy; psoralens and ultraviolet A (PUVA) |
| 96920 | Excimer laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm |
| 96921 | Excimer laser treatment; 250 to 500 sq cm |
| 96922 | Excimer laser treatment; over 500 sq cm |
| 96567 | Photodynamic therapy by external application of light, performed by staff, per day |
| 96573 | Photodynamic therapy with physician or QHP illumination of the photosensitizer, per day |
| 96574 | Debridement of premalignant lesions followed by photodynamic therapy with physician or QHP illumination, per day |
| J7308 | Aminolevulinic acid HCl for topical administration, 20%, single unit dosage form (354 mg) |
Radical Shift: Skin Substitute Reimbursement
Starting January 1, 2026, CMS pays for most skin substitutes as incident-to supplies at a flat rate of about $127.28 per square centimeter, before geographic adjustment, in both physician offices and hospital outpatient departments. This replaces average sales price-based payment for those products.
Products licensed as biologics under the Public Health Service Act stay on ASP + 6%. The application procedure is still reported with 15271 to 15278.
Practices must evaluate acquisition cost against the flat rate to avoid margin erosion.
Flat-rate skin substitute payment can quietly erase margins.
We analyze acquisition cost, payer mix, and claim-level data to prevent financial loss.
Guarantee: We’ll identify whether skin substitute billing is hurting your bottom line.
Surface Radiation Therapy CPT® Codes
New for 2026, these codes replace 77401 (deleted) and Category III code 0394T for superficial and orthovoltage radiation of skin cancers.
| CPT® Code | Description |
|---|---|
| 77436 | Surface radiation therapy, superficial or orthovoltage; treatment planning and simulation-aided field setting |
| 77437 | Superficial radiation treatment delivery, 150 kV or less, per fraction (eg, electronic brachytherapy) |
| 77438 | Orthovoltage radiation treatment delivery, over 150 kV up to 500 kV, per fraction |
| +77439 | Ultrasound image guidance for placement of treatment fields; reported once per course with 77437 or 77438 |
Radiation coding errors create high-dollar denials.
Energy documentation and correct add-on usage are critical under the new code family.
Guarantee: We’ll uncover where radiation claims are breaking down.
Common Dermatology Billing Modifiers
| Modifier | Common Use |
|---|---|
| -25 | Separate E/M on the same day as a procedure |
| -59 | Distinct procedural service |
| -XS | Medicare: separate structure or lesion (the more specific alternative to -59) |
| -51 | Multiple procedures in the same session |
| -24 | Unrelated E/M during a global period |
| -79 | Unrelated procedure during a postoperative period |
| -76 | Repeat procedure by the same provider |
| -RT / -LT | Right or left side |
| -50 | Bilateral procedure |
| -JW | Drug amount discarded (Medicare Part B, single-dose containers) |
| -JZ | No drug discarded (Medicare Part B, single-dose containers) |
Modifier misuse remains one of dermatology’s biggest denial causes.
-25, -59, -JW, and -JZ errors are frequently flagged in automated edits.
Guarantee: We’ll identify modifier-driven denial trends in your practice.
Common ICD-10-CM Codes in Dermatology
| ICD-10 Code | Description |
|---|---|
| L40.0 | Psoriasis vulgaris |
| L70.0 | Acne vulgaris |
| L20.9 | Atopic dermatitis, unspecified |
| L57.0 | Actinic keratosis |
| L82.1 | Other seborrheic keratosis |
| D23.5 | Other benign neoplasm of skin of trunk |
| C44.91 | Basal cell carcinoma of skin, unspecified |
| C44.319 | Basal cell carcinoma of skin of other parts of face |
| C44.02 | Squamous cell carcinoma of skin of lip |
| D48.5 | Neoplasm of uncertain behavior of skin (use only when pathology reports uncertain behavior) |
| D49.2 | Neoplasm of unspecified behavior of bone, soft tissue, and skin (before pathology results) |
| Z12.83 | Encounter for screening for malignant neoplasm of skin |
Even correct CPT® codes deny when diagnosis pairing fails medical necessity.
We evaluate CPT®/ICD alignment to reduce preventable denials.
Guarantee: We’ll identify diagnosis mismatches reducing payment.
2026 Dermatology Billing & Compliance Tips
- Document at least 40 minutes of total time for 99215 when billing by time.
- Use updated “extraction” terminology for CPT® 10040.
- Validate skin substitute acquisition costs against the flat Medicare rate.
- Report one primary biopsy code per encounter and match each add-on to its technique.
- Include margins in the excised diameter and wait for pathology before choosing excision codes.
- Apply -JZ/-JW modifiers to separately payable Medicare Part B drugs from single-dose containers.
- Replace 77401 with the new surface radiation therapy codes.
- Select the proper telehealth place of service (POS 02 or 10) and modifier for each payer.
Frequently Asked Questions
What is CPT code 10040?
CPT 10040 is extraction of multiple acne lesions, such as milia, comedones, cysts, or pustules, by marsupialization, opening, or removal. In 2026 the descriptor changed from “acne surgery” to “extraction,” but the code and its 10-day global period are the same.
Is there a CPT code for skin cancer screening?
No. A full-body skin exam is reported with an E/M or preventive visit code, paired with Z12.83. Medicare does not cover routine skin cancer screening without signs or symptoms, so check coverage first. If a suspicious lesion is evaluated, code the visit to that finding instead.
What is the CPT code for a dermatology consult?
Commercial payers that accept consultation codes use 99242 to 99245. Medicare does not pay consultation codes, so report a new patient visit (99202 to 99205) or established patient visit (99212 to 99215) instead.
What is the global period for a punch biopsy?
Punch biopsy codes 11104 and 11105 have a 0-day global period, so follow-up visits are separately billable. Excisions usually carry a 10-day global period.
Can I bill an E/M and a biopsy on the same day?
Yes, if the visit includes a significant, separately identifiable evaluation beyond the decision to biopsy. Append modifier -25 to the E/M and document the separate work clearly.
Final note: dermatology billing in 2026 rewards practices that update templates, document time and technique precisely, and track payment changes for procedures and supplies.
If dermatology denials are rising in 2026, the cause is predictable, and fixable.
From skin substitute restructuring to radiation updates and strict modifier enforcement, Quest National Services has seen these exact breakdowns across dermatology practices.
Guarantee: We’ll uncover your top denial causes and give you a concrete correction plan.
Trademark notice: CPT is a registered trademark of the American Medical Association.
For informational purposes only.

